ESC 365 - Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction

ESC Professional Premium Access

Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction

Session: Smaller trials: cardiac function and remodelling

Topic: Ventricular Remodelling

Speaker: Doctor J. Carberry (Glasgow, GB)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Jaclyn Carberry

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

1 presentation

0 follower

4 more presentations in this session

Strain sUrveillance during Chemotherapy for improving Cardiovascular Outcomes: Results of a Randomized Trial of Cardioprotection for Reduced Myocardial Strain (SUCCOUR-MRI)

Speaker: Professor T. Marwick (Melbourne, AU)

Catheter Ablation versus Medical Rate Control in Atrial Fibrillation with Left Ventricular Systolic Dysfunction and Myocardial Fibrosis - The CAMERA-MRI II Randomized Trial

Speaker: Associate Professor S. Prabhu (Melbourne, AU)

Sacubitril/valsartan compared to valsartan in regressing myocardial fibrosis in stage B heart failure: the REVERSE-LVH Trial

Speaker: Doctor C. Chin (Singapore, SG)

Sacubitril/valsartan in primary prevention of cancer-therapy related cardiac dysfunction in breast cancer patients.

Speaker: Doctor Y. Hsu (Tainan, TW)

Access the full session

Smaller trials: cardiac function and remodelling

Speakers: Doctor J. Carberry, Professor T. Marwick, Associate Professor S. Prabhu, Doctor C. Chin, Doctor Y. Hsu

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources